Source link : https://www.newshealth.biz/health-news/fda-approves-inavolisib-for-pik3ca-mutated-hr-her2%E2%88%92-mbc/
The US Food and Drug Administration (FDA) has approved inavolisib (Itovebi, Genentech) in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−), locally advanced or metastatic breast cancer following recurrence on or after adjuvant endocrine therapy. The FDA also approved the FoundationOne Liquid CDx assay to […]
Author : News Health
Publish date : 2024-10-11 07:52:07
Copyright for syndicated content belongs to the linked Source.